Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

@article{Bresalier2005CardiovascularEA,
  title={Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.},
  author={R. Bresalier and R. Sandler and H. Quan and J. Bolognese and Bettina Oxenius and K. Horgan and C. Lines and R. Riddell and D. Morton and {\'A}. Lanas and M. Konstam and J. Baron},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 11},
  pages={
          1092-102
        }
}
  • R. Bresalier, R. Sandler, +9 authors J. Baron
  • Published 2005
  • Medicine
  • The New England journal of medicine
  • BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside… Expand
    ConditionsColorectal Adenoma
    InterventionDrug

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 1,874 CITATIONS, ESTIMATED 44% COVERAGE

    Celecoxib for the prevention of colorectal adenomatous polyps.

    FILTER CITATIONS BY YEAR

    2003
    2020

    CITATION STATISTICS

    • 50 Highly Influenced Citations

    • Averaged 51 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 28 REFERENCES